Alison E. Simmons
YOU?
Author Swipe
View article: Correction: Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority
Correction: Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority Open
[This corrects the article DOI: 10.1371/journal.pone.0297093.].
View article: Cost-Utility Analysis of COVID-19 Vaccination Strategies for Endemic SARS-CoV-2
Cost-Utility Analysis of COVID-19 Vaccination Strategies for Endemic SARS-CoV-2 Open
Importance With shifting epidemiology and changes in the vaccine funding landscape, resource use considerations for COVID-19 vaccination programs are increasingly important. Objective To assess the cost effectiveness of COVID-19 vaccinatio…
View article: Impact of Adjustment for Differential Testing by Age and Sex on Apparent Epidemiology of SARS-CoV-2 Infection in Ontario, Canada
Impact of Adjustment for Differential Testing by Age and Sex on Apparent Epidemiology of SARS-CoV-2 Infection in Ontario, Canada Open
Communicable disease surveillance typically relies on case counts for estimates of risk, and counts can be strongly influenced by testing rates. In the Canadian province of Ontario, testing rates varied markedly by age, sex, geography and …
View article: Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada
Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada Open
The use of PCV21 may be cost-effective in some populations, depending on the prevalence of IPD serotypes covered by PCV20 and PCV21.
View article: Cost effectiveness of a 21-valent pneumococcal conjugate vaccine in adults: A systematic review of economic evaluations
Cost effectiveness of a 21-valent pneumococcal conjugate vaccine in adults: A systematic review of economic evaluations Open
Pneu-C-21 is likely to be cost-effective in adults within specific age and risk groups. The applicability of the included economic evaluations to adults living in Canada is limited because the serotype-specific incidence of pneumococcal di…
View article: Cost-effectiveness of respiratory syncytial virus vaccination strategies for older Canadian adults: A multi-model comparison
Cost-effectiveness of respiratory syncytial virus vaccination strategies for older Canadian adults: A multi-model comparison Open
A multi-model comparison of Canadian cost-utility models shows that RSV vaccination programs for RSV are likely cost-effective for some groups of older adults in Canada. These findings were consistent across models, despite differences in …
View article: Comparison of 13-, 15- and 20-valent pneumococcal conjugate vaccines in the paediatric Canadian population: A cost-utility analysis
Comparison of 13-, 15- and 20-valent pneumococcal conjugate vaccines in the paediatric Canadian population: A cost-utility analysis Open
Both Pneu-C-15 and Pneu-C-20 are expected to increase QALYs in Canadian children compared to Pneu-C-13 and may be cost-effective interventions.
View article: Derivation and Validation of a Point-based Forecasting Tool for SARS-CoV-2 Critical Care Occupancy
Derivation and Validation of a Point-based Forecasting Tool for SARS-CoV-2 Critical Care Occupancy Open
Background The requirement for critical care in even a modest fraction of SARS-CoV-2 infected individuals made ICU resources an important societal chokepoint during the recent pandemic. We developed a simple regression-based point score in…
View article: Cost-utility analysis of current COVID-19 vaccination program recommendations in Canada
Cost-utility analysis of current COVID-19 vaccination program recommendations in Canada Open
Background As COVID-19 becomes established as an endemic disease with widespread population immunity, there is uncertainty about the economic benefit of ongoing COVID-19 vaccination programs. We assessed the cost-effectiveness of a COVID-1…
View article: Cost-utility analysis of COVID-19 vaccination strategies for endemic SARS-CoV-2 circulation in Canada
Cost-utility analysis of COVID-19 vaccination strategies for endemic SARS-CoV-2 circulation in Canada Open
Background With shifting epidemiology and changes in the vaccine funding landscape, resource use considerations for ongoing COVID-19 vaccination programs are increasingly important. We assessed the cost-effectiveness of COVID-19 vaccinatio…
View article: Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada
Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada Open
Background A 21-valent pneumococcal conjugate vaccine (PCV21) was recently authorized in Canada to protect adults against invasive pneumococcal disease (IPD). Objective To assess the cost-effectiveness of PCV21 compared to current Canadian…
View article: Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost–utility analysis
Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost–utility analysis Open
Vaccination programs for RSV in some groups of older Canadians with underlying medical conditions are likely cost-effective. These findings can inform the design of vaccination programs.
View article: Association Between Seasonal Respiratory Virus Activity and Invasive Pneumococcal Disease in Central Ontario, Canada
Association Between Seasonal Respiratory Virus Activity and Invasive Pneumococcal Disease in Central Ontario, Canada Open
Background In central Ontario, influenza, respiratory syncytial virus (RSV), and invasive pneumococcal disease (IPD) follow similar seasonal patterns, peaking in winter. We aimed to quantify the independent and joint impact of influenza A,…
View article: Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants
Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants Open
Prophylactic interventions can substantially reduce RSV disease in infants, and more focused nirsevimab programs are the most cost-effective option at current product prices.
View article: Cost-effectiveness of respiratory syncytial virus vaccination strategies for older Canadian adults: a multi-model comparison
Cost-effectiveness of respiratory syncytial virus vaccination strategies for older Canadian adults: a multi-model comparison Open
Background Two respiratory syncytial virus (RSV) vaccines are currently approved for use in adults aged 60 years and older in Canada. Economic analyses have shown that adult RSV vaccination programs may be cost-effective, particularly when…
View article: Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority
Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority Open
Background We previously demonstrated that when vaccines prevent infection, the dynamics of mixing between vaccinated and unvaccinated sub-populations is such that use of imperfect vaccines markedly decreases risk for vaccinated people, an…
View article: Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants
Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants Open
Background Health Canada recently authorized the RSVpreF pregnancy vaccine and nirsevimab to protect infants against respiratory syncytial virus (RSV) disease. Objective Assess the cost-effectiveness of RSVpreF and nirsevimab programs in p…
View article: Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysis
Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysis Open
Background Vaccines against respiratory syncytial virus (RSV) have the potential to reduce disease burden and costs in Canadians, but the cost-effectiveness of RSV vaccination programs for older adults is unknown. We evaluated the cost-eff…
View article: Impact of community mask mandates on SARS-CoV-2 transmission in Ontario after adjustment for differential testing by age and sex
Impact of community mask mandates on SARS-CoV-2 transmission in Ontario after adjustment for differential testing by age and sex Open
Mask use for prevention of respiratory infectious disease transmission is not new but has proven controversial during the SARS-CoV-2 pandemic. In Ontario, Canada, irregular regional introduction of community mask mandates in 2020 created a…
View article: A STAKEHOLDER-PARTNERED APPROACH TO INEQUITIES AFFECTING HOME HEALTH CARE WORKERS, OLDER ADULTS, AND CAREGIVERS
A STAKEHOLDER-PARTNERED APPROACH TO INEQUITIES AFFECTING HOME HEALTH CARE WORKERS, OLDER ADULTS, AND CAREGIVERS Open
Home health aides (HHAs) provide on-site support for homebound older adults with cognitive impairments, while lessening strain on familial caregivers. However, HHAs face structural challenges in work-related transportation. Massachusetts G…
View article: Impact of Adjustment for Differential Testing by Age and Sex on Apparent Epidemiology of SARS-CoV-2 Infection in Ontario, Canada
Impact of Adjustment for Differential Testing by Age and Sex on Apparent Epidemiology of SARS-CoV-2 Infection in Ontario, Canada Open
Background Surveillance of communicable diseases typically relies on case counts for estimates of risk, and counts can be strongly influenced by testing rates. In the Canadian province of Ontario, testing rates varied markedly by age, sex,…
View article: Impact of Community Masking on SARS-CoV-2 Transmission in Ontario after Adjustment for Differential Testing by Age and Sex
Impact of Community Masking on SARS-CoV-2 Transmission in Ontario after Adjustment for Differential Testing by Age and Sex Open
Background Use of masks and respirators for prevention of respiratory infectious disease transmission is not new, but has proven controversial, and even politically polarizing during the SARS-CoV-2 pandemic. In the Canadian province of Ont…
View article: Relative pandemic severity in Canada and four peer nations during the SARS-CoV-2 pandemic
Relative pandemic severity in Canada and four peer nations during the SARS-CoV-2 pandemic Open
Canada outperformed several peer countries that aimed for mitigation rather than elimination of SARS-CoV-2 in the first two years of the pandemic, with substantial numbers of lives saved and economic costs averted. However, a comparison wi…
View article: Hepatitis B and C in individuals with a history of antipsychotic medication use: A population-based evaluation
Hepatitis B and C in individuals with a history of antipsychotic medication use: A population-based evaluation Open
Background A better understanding of links between mental illness and risk of bloodborne infectious disease could inform preventive and therapeutic strategies in individuals with mental illness. Methods We performed a cross-sectional study…
View article: Vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Ontario, Canada: A retrospective cohort study
Vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Ontario, Canada: A retrospective cohort study Open
Background Vaccines against SARS-CoV-2 have been shown to reduce risk of infection as well as severe disease among those with breakthrough infection in adults. The latter effect is particularly important as immune evasion by Omicron varian…